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INTRODUCTION
Propofol is an anesthetic agent used for induction and main-
tenance of general anesthesia and also for sedation during 
minor procedures. However, maintenance of airway patency is 
a primary concern under propofol sedation.1 Although propo-
fol is considered to induce sedation and airway obstruction in 
a dose-dependent manner, there have been few reports inves-
tigating this relationship.2,3 Obstructive sleep apnea-hypopnea 
syndrome (OSAHS) involves recurring episodes of total (ap-
nea) or partial (hypopnea) obstruction of the airways during 
sleep.4 Disastrous respiratory outcomes have been reported 
during perioperative management of OSAHS patients;5 there-
fore, the sedative used must be carefully titrated to avoid 
oversedation. Understanding the dose-response relationship of 
sedation and airway obstruction is fundamental for the safe 
use of propofol, especially when dealing with patients who are 
at a greater risk of airway collapse.
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The purpose of this study was to investigate the relations 
between the effect-site concentration (Ce) of propofol and the 
degrees of sedation and airway obstruction in patients with 
OSAHS receiving the sedative through a target-controlled in-
fusion (TCI) device. 
MATERIALS AND METHODS
This study was approved by the Yonsei University Health Sys-
tem Ethics Committee, and informed consent was obtained 
from all patients before including them in the study. Twenty-
five participants, all above 20 years of age and with an Ameri-
can Society of Anesthesiologists classification I or II, were se-
dated in order to perform drug-induced sleep endoscopy, i.e., 
assessing the cause of the apnea and snoring by pharmaco-
logically artificially inducing the patient into a light sleep and 
performing flexible endoscopy of the upper airway. The pa-
tients presented subjective symptoms such as snoring, day-
time sleepiness, morning headache, sleep disturbance, fa-
tigue, and an apnea-hypopnea index (AHI) >5 recorded by un-
attended polysomnography [8-channel polygraphy: SpO2, heart 
rate (HR), flow cannula sensor, actometer, abdominal & tho-
racic external effort-sensor, electrooculogram; MAP Poly-
MESAM, Medicair, Milano, Italy]. OSAHS was categorized as 
mild (AHI: 5–15), moderate (AHI: 15–30), and severe (AHI: 
>30), as assessed by polysomnography.6 Patients were exclud-
ed from the study if they refused to participate or had hepatic, 
renal, or pulmonary disease; a history of chronic drug use with 
the potential to affect the central nervous system; a history of 
adverse drug reactions; or a history of heart block. Patients 
with impaired hearing, neurological deficits, or a Glasgow 
Coma Scale score under 15 were also excluded. 
After arrival at the operating room, each patient’s electro-
cardiogram, peripheral oxygen saturation (SpO2), non-inva-
sive arterial pressure, and bispectral index (BIS; BIS® monitor, 
Aspect medical Systems, Natick, MA, USA) were monitored 
and recorded at 5-min intervals throughout the whole proce-
dure. Oxygen was given to the patients at 5 L/min via a face-
mask and nasal cannula. Hartmann’s solution of 4 mL/kg/hr 
was administered until all procedures ended. The temperature 
and humidity of the operating room were maintained at 22–
24°C and 60%, respectively. 
As an antisialagogue, 0.1 mg glycopyrrolate was injected in-
travenously. After confirmation of stable vital signs [<10% of 
baseline mean arterial pressure (MAP) and HR], sedation was 
induced by 2% propofol (Fresofol 2%TM; Fresenius Kabi, Aus-
tria) using a commercial TCI pump (Orchestra® Base Primea; 
Fresenius Vial, France). Operation of the pump was based on 
the pharmacokinetic model reported by Schnider, et al.7,8 The 
initial Ce of propofol was 0.5 μg/mL, and the Ce was increased 
at a rate of 0.1 μg/mL every 5 minutes by one anesthesiologist. 
The degrees of sedation and airway obstruction, MAP, HR, re-
spiratory rate, SpO2, and BIS score were assessed and record-
ed by another anesthesiologist who was not aware of the pro-
pofol Ce just before it was increased for the next step. The 
degree of sedation was evaluated based on the Observer’s As-
sessment of Alertness/Sedation (OAA/S) scoring system,9 and 
airway obstruction was assessed using a four-category scale 
(Table 1).2 When the MAP was lower than 60 mm Hg or sys-
tolic arterial pressure was lower than 90 mm Hg, 4 mg ephed-
rine was injected intravenously, and when HR dropped below 
50 beats/min, 0.5 mg atropine was injected intravenously. 
When bradypnea or hypoxia (SpO2 below 90%) occurred, oxy-
gen, and ventilatory support were provided to the patients im-
mediately via jaw thrust. When the OAA/S score reached 5, 
we completed the study, and a flexible nasal endoscopy was 
then performed to confirm apneic events and correlate them 
with pharyngeal collapse patterns. If the endoscopy failed due 
to patient movement, the Ce of propofol was gradually in-
creased by 0.1 μg/mL until the procedure was successful.
The probability (P) of a given level of effect (sedation or air-
way obstruction) was related to propofol Ce using the follow-
ing sigmoidal equation. 
Pij (effect≥m)=
Ceij
λi
Ceij
λi
50(m)j
λiCe+
In this equation, Pij (effect≥m) is the probability for the ith 
individual that the jth effect score is equal to or greater than (i.e., 
“deeper than”) a given discrete level (m). Ceij is propofol Ce for 
the ith individual at the jth observation. Ce50(m)i is the steady-
state Ce associated with 50% probability corresponding to the 
ith patient, and λi is the steepness of the probability versus the 
concentration curve corresponding to the ith patient. 
The complete model for each of the two response studies 
consisted of four and three separate models, one for each of the 
following scores: 2, 3, 4, and 5 for sedation and 2, 3, and 4 for 
airway obstruction, respectively. Sedation and airway obstruc-
tion scores of 1 were not included, as these were baseline scores 
measured before propofol was applied. Model parameters 
Table 1. Descriptions of the Observer’s Assessment of Alertness/Sedation (OAA/S) Scores and Airway Obstruction Scores
OAA/S score Airway obstruction score
1. Responds readily to name spoken in normal tone 1. Normal breathing
2. Lethargic response to name spoken in normal tone 2. Deep breathing
3. Responds only after name is spoken loudly and/or repeatedly 3. Snoring
4. Responds only after mild prodding or shaking 4. Severe airway obstruction
5. Does not respond to mild prodding or shaking −
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were estimated using the function “LIKELIHOOD LAPLACE 
METHOD=conditional” in Nonlinear Mixed Effects Modeling 
(NONMEM) software (version VII; GloboMax, Hanover, MD, 
USA). For each analysis, NONMEM computed the minimum 
value of the objective function, a statistic that was proportion-
al to the negative of twice the log likelihood of the data. The 
inter-individual random variability of each Ce50 was modeled 
using a log-normal model, whereas the inter-individual ran-
dom variability of γ was fixed at zero. After obtaining the pop-
ulation base model, a forward inclusion and backward elimi-
nation approach was used in consecutive NONMEM runs to 
determine the relevant covariates among all covariates [age, 
sex, height, weight, AHI, and body mass index (BMI)]. A covari-
ate was considered significant if its inclusion lowered the min-
imum value of the objective function by at least 3.85 points. 
The difference in the minimum value of the objective function 
between two nested models approximately follows a chi-
square distribution and could therefore be used to investigate 
statistical significance [chi-square statistics equaled 3.84 at 
the level of significance (p<0.05), with one degree of freedom]. 
A non-parametric bootstrap procedure was performed for in-
ternal validation using Perl-speaks-NONMEM (PsN) (version 
3.6.2, http://psn.sourceforge.net), and the original data set was 
randomly sampled to generate 2000 bootstrap replicates. We 
obtained the 95% confidence intervals of the nonparametric 
bootstrap replicates and compared final model parameter es-
timates with them. 
RESULTS 
Twenty-five patients who met the selection criteria were stud-
ied. Demographics of the enrolled patients are summarized in 
Table 2. Relations between propofol Ce and the observed seda-
tion and airway obstruction scores are shown in Fig. 1. Incre-
ments in propofol Ce were associated with increased depth of 
sedation and airway obstruction (Fig. 1) and decreased values 
of BIS (Fig. 2). The sedation and airway obstruction effects were 
best described with a sigmoidal Emax model using propofol 
Ce. The estimated model parameters of the ultimately select-
ed pharmacodynamic model and bootstrap estimates for 
each level of sedation and airway obstruction are summarized 
in Table 3. Based on our observations, all sedation- and airway 
obstruction-related parameters were estimated with adequate 
precision (relative standard error <50%) and were also reli-
Table 2. Demographics and General Characteristics of the Patients
Clinical variables Data values
Sex (male/female) 21/4
Age (yrs) 47.8±10.1
Height (cm) 168.1±7.3
Weight (kg) 75.3±12.0
Body mass index (kg/m2) 26.5±2.9
Apnea-hypopnea index 42.4±21.5
Data are presented as mean±SD or as absolute numbers. 
Fig. 2. The relation between propofol effect-site concentration and the 
observed bispectral index (BIS). The scattered dots are the raw data of 
BIS observed for all patients.
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Fig. 1. Description of the raw data. Observer’s Assessment of Alertness/Sedation score (A) and airway obstruction score (B) versus propofol effect-
site concentration.
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able, as they were within the 95% confidence intervals of the 
bootstrap estimates. The predicted Ce50(m) values correspond-
ing to sedation scores (m) ≥2, 3, 4, and 5 were 1.61, 1.78, 1.91, 
and 2.17 μg/mL, respectively. The predicted Ce50(m) values cor-
responding to airway-obstruction scores (m) ≥2, 3, and 4 were 
1.53, 1.64, and 2.09 μg/mL, respectively. Significant correla-
tions were found between AHI and Ce50(4) for airway obstruc-
tion with a negative slope (p<0.0001) and AHI and BMI with a 
positive slope (p<0.0001), as shown in Fig. 3. The pharmacody-
namic model including AHI significantly improved the per-
formance of the base model based on the likelihood ratio test, 
decreasing the minimum value of the objective function from 
507.0 to 501.4 (p=0.018). Considering that AHI was the only fac-
tor that showed correlation with propofol C50(4) for airway ob-
struction, we included this as a covariate in our model (Table 3). 
Typical probability curves of population data for each sedation 
and airway-obstruction score are shown in Fig. 4. The effect of 
AHI on the probability of an airway obstruction score of 4, as 
evaluated by estimation, is presented in Fig. 5. Propofol Ce50(4) 
values in patients with AHI scores of 10, 40, and 70 were pre-
dicted to be 2.41, 2.05, and 1.81 μg/mL, respectively. 
DISCUSSION
In this study, we obtained the propofol Ce for each sedation 
Table 3. Summary of the Results of the Final Population Pharmacodynamic Models Selected for Sedation and Airway Obstruction
Parameter Population mean value (%RSE) Interindividual variability (%CV) Median (2.5–97.5%)
Sedation
C50(2) (μg/mL) 1.61 (3.40) 0.016 (12.65) 1.61 (1.46–1.71)
C50(3) (μg/mL) 1.78 (3.78) 0.025 (15.65) 1.80 (1.57–1.91)
C50(4) (μg/mL) 1.91 (4.42) 0.038 (19.42) 1.94 (1.69–2.07)
C50(5) (μg/mL) 2.17 (5.85) 0.066 (25.75) 2.17 (1.98–2.58)
λ(2) 12.8 (22.11) - 12.5 (9.39–19.07)
λ(3) 13.2 (26.44) - 13.1 (9.12–25.51)
λ(4) 14.7 (26.46) - 15.0 (9.21–25.85)
λ(5) 22.8 (38.33) - 23.4 (9.51–55.99)
Airway obstruction
C50(2) (μg/mL) 1.53 (3.59) 0.016 (12.61) 1.54 (1.38–1.68)
C50(3) (μg/mL) 1.64 (3.09) 0.016 (12.61) 1.63 (1.56–1.72)
C50(4) (μg/mL)=θ1–θ2*(AHI-46)
θ1  1.98 (6.52)
0.065 (25.46)
2.05 (1.64–2.32)
θ2  0.012 (48.39) 0.012 (0.0008–0.02)
λ(2) 26.3 (26.08) - 25.1 (15.04–37.56)
λ(3) 14.4 (33.96) - 16.5 (1.19–27.61)
λ(4) 7.68 (32.55) - 7.79 (2.20–13.16)
C50(m), propofol effect-site concentration associated with a 50% probability of being at least at the “m” score; λ, steepness of the concentration-versus-response 
relationship curve; AHI, apnea-hypopnea index; RSE, relative standard error; CV, coefficient of variation.
A B
Fig. 3. Linear regression between AHI and propofol Ce50(4) for severe airway obstruction (A) and between AHI and BMI (B). The following equations 
were used, for graph A: Y=-0.0124 X+2.831 (r=0.41; p<0.0001) and for graph B: Y=0.0726 X+23.294 (r=0.59; p<0.0001). AHI, apnea-hypopnea index; BMI, 
body mass index.
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and airway-obstruction score in patients with OSAHS and 
found that the AHI was a significant covariate of Ce50 in the 
dynamic relationship between propofol Ce and severe airway 
obstruction. Our study is the first clinical investigation in which 
pharmacodynamic modeling of sedation and airway obstruc-
tion in patients with OSAHS has been evaluated.
OSAHS is characterized by repetitive pharyngeal collapse 
during sleep, a process that constricts the pathway for airflow 
and causes periods of airflow reduction or cessation and a con-
sequent reduction in blood oxygen levels.4 In the clinic, OSAHS 
is diagnosed using polysomnography and is defined by an 
AHI of five or more episodes per hour.10 Doses or concentra-
tions of anesthetic drugs used for sedation need to be reduced 
for the safety of patients with sleep apnea.11,12 However, no stud-
ies have confirmed the relationship between the kinetics of 
sedative drugs and the degrees of sedation and airway obstruc-
tion in these patients. It would be clinically advantageous if the 
appropriate Ce of propofol for each level of sedation and air-
way obstruction could be predicted and applied. A nonlinear 
dynamic model was chosen to describe the relationship be-
tween propofol Ce and sedation and airway-obstruction scores, 
as the data were expected to fit a sigmoid slope. 
Based on our results, increments in propofol Ce were asso-
ciated with increased depth of sedation and severity of airway 
obstruction.3 However, the differences between the predicted 
Ce50 values for each level of sedation were small (about 0.1–0.3 
μg/mL), and the λ values for each probability curve of seda-
tion were relatively high (≥12.8). These model parameters for 
sedation indicate that unwanted deep sedation or inadequate 
sedation might easily happen. Thus, Ce needs to be carefully 
titrated to achieve a certain level of sedation that is consistent 
with the known narrow therapeutic range of propofol.1,13,14 Giv-
en that our pharmacodynamic model was developed on the 
basis of data collected when using propofol alone without pre-
medication or analgesics, propofol Ce should be reduced to 
avoid oversedation when other drugs, which may have syner-
gistic effects on sedation, are concurrently administered.15,16 
Special attention should be paid to the maintenance of air-
way patency during sedation in OSAHS patients, as Ce50 values 
for snoring or severe airway obstruction were not distinctively 
different from the Ce50 values for moderate sedation from a 
clinical point of view. There were no data available for healthy 
individuals without OSAHS that we could use for comparison. 
When we compared our results to the findings of Fábregas, et 
al.,2 we found that our Ce50 value (1.64 μg/mL) for snoring was 
lower than their reported Ce50 value (2.98 μg/mL) for patients 
with Parkinson disease. It is commonly expected that patients 
with central nervous system dysfunction might be more sensi-
tive to the hypnotic effect of propofol than healthy individuals. 
However, the airway of patients with OSAHS proved to be more 
A B
Fig. 4. Probability curves for propofol effect-site concentration versus each level of sedation (A) and airway obstruction (B). m, discrete level of seda-
tion or airway obstruction.
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vulnerable to propofol than that of patients with Parkinson dis-
ease. Moreover, their pharmacokinetic values based on Marsh, 
et al.17 might be somewhat different from our pharmacokinet-
ic values based on Schnider, et al.7,8 
Sedation with propofol changes the macroarchitecture of 
sleep, and sedation-induced sleep does not seem to correlate 
well with natural sleep based on previous studies,18,19 although 
there is an ongoing debate concerning this. Our finding is 
meaningful in that the AHI, evaluated during natural sleep, 
proved to be a good covariate for severe airway obstruction 
during propofol sedation. The simulated propofol Ce50 for se-
vere airway obstruction in a patient with an AHI of 70 is around 
three fourths of that in a patient with an AHI of 10. In patients 
with an AHI of 70, the propofol Ce50 for severe airway obstruc-
tion was similar to the propofol Ce50 for OAA/S 3 sedation (1.81 
μg/mL and 1.78 μg/mL, respectively), suggesting that these pa-
tients are at risk of having severe airway obstruction even dur-
ing moderate sedation. Patients with high AHI values are 
more susceptible to airway obstruction and need more atten-
tion during propofol-induced sedation.
Obesity is associated with a 12- to 30-fold increased risk of 
OSAHS relative to the normal population, and OSAHS is found 
in 40% of obese females and 50% of obese males.20 BMI repre-
senting the severity of obesity correlated well with AHI in our 
study, confirming the findings of a previous report in which it 
was found to be an independent risk factor for snoring in Chi-
nese women.21 Hence, we expected that BMI would be a po-
tential covariate and could explain the interpatient variability 
in pharmacodynamic modeling for airway obstruction; how-
ever, the severity of obesity did not prove to be a significant co-
variate. One explanation for this outcome might be that there 
were only two obese patients with a BMI value higher than 30, 
while the average AHI of the population was relatively high. 
The limitations of our study included our lack of permission 
to take blood samples to measure propofol concentration and 
our assumption that the Schnider model adequately charac-
terized the patient population that we studied. Our results 
should thus be interpreted with caution, as the parameters of 
the pharmacodynamic model are dependent on the selected 
pharmacokinetic model. While the Schnider model is not per-
fect, it has fewer limitations than other pharmacokinetic mod-
els for propofol and therefore has the potential to become the 
recommended model to use when testing TCI.7,8,22
We conclude that increments in propofol Ce are associated 
with increased depth of sedation and airway obstruction when 
determining the narrow therapeutic range of propofol in pa-
tients with OSAHS. AHI significantly affects the pharmacody-
namic relationship between propofol Ce and severe airway 
obstruction. Propofol Ce for severe airway obstruction can be 
predicted for individual OSAHS patients with different AHI val-
ues, and patients with high AHI values need more attention in 
order to maintain airway patency during propofol-induced se-
dation.
ACKNOWLEDGEMENTS
This work was conducted in the department of Anesthesiolo-
gy and Pain Medicine, Severance Hospital, Seoul, Korea. Sup-
port was provided only from departmental sources. 
REFERENCES
1. Skues MA, Prys-Roberts C. The pharmacology of propofol. J Clin 
Anesth 1989;1:387-400.
2. Fábregas N, Rapado J, Gambús PL, Valero R, Carrero E, Salvador 
L, et al. Modeling of the sedative and airway obstruction effects of 
propofol in patients with Parkinson disease undergoing stereo-
tactic surgery. Anesthesiology 2002;97:1378-86.
3. Eastwood PR, Platt PR, Shepherd K, Maddison K, Hillman DR. Col-
lapsibility of the upper airway at different concentrations of pro-
pofol anesthesia. Anesthesiology 2005;103:470-7.
4. Sundaram S, Bridgman SA, Lim J, Lasserson TJ. Surgery for obstruc-
tive sleep apnoea. Cochrane Database Syst Rev 2005:CD001004.
5. Benumof JL. Creation of observational unit may decrease sleep ap-
nea risk. APSF Newsletter 2002;17:39.
6. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive 
sleep apnea: a population health perspective. Am J Respir Crit 
Care Med 2002;165:1217-39.
7. Schnider TW, Minto CF, Gambus PL, Andresen C, Goodale DB, 
Shafer SL, et al. The influence of method of administration and 
covariates on the pharmacokinetics of propofol in adult volun-
teers. Anesthesiology 1998;88:1170-82.
8. Schnider TW, Minto CF, Shafer SL, Gambus PL, Andresen C, Goo-
dale DB, et al. The influence of age on propofol pharmacodynam-
ics. Anesthesiology 1999;90:1502-16.
9. Chernik DA, Gillings D, Laine H, Hendler J, Silver JM, Davidson AB, 
et al. Validity and reliability of the Observer’s Assessment of Alert-
ness/Sedation Scale: study with intravenous midazolam. J Clin 
Psychopharmacol 1990;10:244-51.
10. Collop NA, Anderson WM, Boehlecke B, Claman D, Goldberg R, 
Gottlieb DJ, et al. Clinical guidelines for the use of unattended por-
table monitors in the diagnosis of obstructive sleep apnea in adult 
patients. Portable Monitoring Task Force of the American Academy 
of Sleep Medicine. J Clin Sleep Med 2007;3:737-47.
11. Dhonneur G, Combes X, Leroux B, Duvaldestin P. Postoperative 
obstructive apnea. Anesth Analg 1999;89:762-7.
12. Chung F, Crago RR. Sleep apnoea syndrome and anaesthesia. 
Can Anaesth Soc J 1982;29:439-45.
13. Krauss B, Green SM. Sedation and analgesia for procedures in 
children. N Engl J Med 2000;342:938-45.
14. Jung M, Hofmann C, Kiesslich R, Brackertz A. Improved sedation 
in diagnostic and therapeutic ERCP: propofol is an alternative to 
midazolam. Endoscopy 2000;32:233-8.
15. Olmos M, Ballester JA, Vidarte MA, Elizalde JL, Escobar A. The 
combined effect of age and premedication on the propofol require-
ments for induction by target-controlled infusion. Anesth Analg 
2000;90:1157-61.
16. McClune S, McKay AC, Wright PM, Patterson CC, Clarke RS. Syn-
ergistic interaction between midazolam and propofol. Br J An-
aesth 1992;69:240-5.
17. Marsh B, White M, Morton N, Kenny GN. Pharmacokinetic model 
driven infusion of propofol in children. Br J Anaesth 1991;67:41-8.
18. Rabelo FA, Küpper DS, Sander HH, Fernandes RM, Valera FC. 
Polysomnographic evaluation of propofol-induced sleep in pa-
tients with respiratory sleep disorders and controls. Laryngoscope 
http://dx.doi.org/10.3349/ymj.2015.56.5.14081414
Propofol-Induced Sedation and Airway Obstruction
2013;123:2300-5.
19. Rabelo FA, Braga A, Küpper DS, De Oliveira JA, Lopes FM, de 
Lima Mattos PL, et al. Propofol-induced sleep: polysomnographic 
evaluation of patients with obstructive sleep apnea and controls. 
Otolaryngol Head Neck Surg 2010;142:218-24.
20. Kyzer S, Charuzi I. Obstructive sleep apnea in the obese. World J 
Surg 1998;22:998-1001.
21. Li QY, Huang SG, Li M, Liu JL, Wan HY. BMI is an independent risk 
factor for snoring in Chinese women aged over 30 years. Sleep 
Breath 2009;13:289-93. 
22. Masui K, Upton RN, Doufas AG, Coetzee JF, Kazama T, Mortier EP, 
et al. The performance of compartmental and physiologically 
based recirculatory pharmacokinetic models for propofol: a com-
parison using bolus, continuous, and target-controlled infusion 
data. Anesth Analg 2010;111:368-79. 
